Law360, Phoenix (March 29, 2018, 11:30 PM EDT) -- A Phoenix federal jury began deliberations Thursday in the first bellwether trial in multidistrict litigation over claims that device maker Bard’s clot-stopping vein implants splintered and migrated towards patients’ hearts, after Bard closed its case by arguing evidence concerning predecessor implants and FDA warnings were red herrings.
Plaintiff Sherri Booker, who was 37 at the time a surgeon implanted a Bard G2 filter into her inferior vena cava, says the device’s power to protect her from pulmonary emboli was not worth the nightmare that followed, when one of its legs broke off. Booker eventually had an open-heart surgery that recovered some...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!